K Lenz1, A Gegenhuber, F Firlinger, G Lohr, P Piringer. 1. Interne Abteilung mit Intensivstation, Konventhospital Barmherzige Brüder Linz, Seilerstätte 2, 4020, Linz, Österreich, kurt.lenz@bblinz.at.
Abstract
BACKGROUND: In a pilot study, 9 patients (39-48 years) with acute decompensated heart failure and a cardiac index (CI) of 1.9 ± 0.3 l/min/m(2) were included after exclusion of an underlying hepatic disease. MATERIALS AND METHODS: The effect of levosimendan on liver blood flow and liver function was measured with the LiMON(®) system using the indocyane green plasma disappearance rate (ICG PDR). RESULTS: Levosimendan (Simdax(®)) infusion resulted in a significant increase of the CI, thus, achieving normal ranges of 2.9 ± 0.9 l/min/m(2) after 4 h and 3.3 ± 1 l/min/m(2) (p = 0.003) after 24 h. ICG PDR increased from 8.2 ± 0.8 % to 10.2 + 1.8 % after 4 h and to 11.9 ± 2.9 % after 24 h (p = 0.04). DISCUSSION: The reason for the early increase in systemic blood flow with no concomitant change in ICG PDR is not clear. A primary increase in liver blood flow with sustained low liver function might be one explanation; a low flow-mediated increased release of cytokines from liver cells with consequent deterioration of liver function is another possible explanation.
BACKGROUND: In a pilot study, 9 patients (39-48 years) with acute decompensated heart failure and a cardiac index (CI) of 1.9 ± 0.3 l/min/m(2) were included after exclusion of an underlying hepatic disease. MATERIALS AND METHODS: The effect of levosimendan on liver blood flow and liver function was measured with the LiMON(®) system using the indocyane green plasma disappearance rate (ICG PDR). RESULTS:Levosimendan (Simdax(®)) infusion resulted in a significant increase of the CI, thus, achieving normal ranges of 2.9 ± 0.9 l/min/m(2) after 4 h and 3.3 ± 1 l/min/m(2) (p = 0.003) after 24 h. ICG PDR increased from 8.2 ± 0.8 % to 10.2 + 1.8 % after 4 h and to 11.9 ± 2.9 % after 24 h (p = 0.04). DISCUSSION: The reason for the early increase in systemic blood flow with no concomitant change in ICG PDR is not clear. A primary increase in liver blood flow with sustained low liver function might be one explanation; a low flow-mediated increased release of cytokines from liver cells with consequent deterioration of liver function is another possible explanation.
Authors: A Gornikiewicz; T Sautner; C Brostjan; B Schmierer; R Függer; E Roth; F Mühlbacher; M Bergmann Journal: FASEB J Date: 2000-06 Impact factor: 5.191
Authors: Anna Laura Pasqui; Silvia Maffei; Michela Di Renzo; Gerarda Pompella; Alberto Auteri; Luca Puccetti Journal: Int J Cardiol Date: 2011-01-06 Impact factor: 4.164
Authors: G Plenz; Z F Song; T D Tjan; C Koenig; H A Baba; M Erren; M Flesch; T Wichter; H H Scheld; M C Deng Journal: Eur J Heart Fail Date: 2001-08 Impact factor: 15.534
Authors: Alexander Geppert; Angela Steiner; Gerlinde Zorn; Georg Delle-Karth; Maria Koreny; Markus Haumer; Peter Siostrzonek; Kurt Huber; Gottfried Heinz Journal: Crit Care Med Date: 2002-09 Impact factor: 7.598
Authors: Valentin Fuhrmann; Nikolaus Kneidinger; Harald Herkner; Gottfried Heinz; Mariam Nikfardjam; Anja Bojic; Peter Schellongowski; Bernhard Angermayr; Reinhard Kitzberger; Joanna Warszawska; Ulrike Holzinger; Peter Schenk; Christian Madl Journal: Intensive Care Med Date: 2009-06-09 Impact factor: 17.440
Authors: Elena Grossini; Kevin Bellofatto; Serena Farruggio; Lorenzo Sigaudo; Patrizia Marotta; Giulia Raina; Veronica De Giuli; David Mary; Piero Pollesello; Rosalba Minisini; Mario Pirisi; Giovanni Vacca Journal: PLoS One Date: 2015-04-16 Impact factor: 3.240